-
-
-
-
-
-
-
William Blair Shuffles Analyst Conviction List for April 2026
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) PT Raised to $74 at Bloom Burton & Co.
-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE): "Buyers on best-in-disease Phase 3 results"
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) Reiterated at Overweight by JPMorgan
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) PT Raised to $57 at RBC Capital
-
-
-
-
-
-
-
Chardan Capital Markets Starts Xenon Pharmaceuticals (XENE) at Buy
-
445,866 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

